{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:07:45Z","timestamp":1793822865377,"version":"4.6.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1012903","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000}}],"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006234","name":"Sandia National Laboratories","doi-asserted-by":"publisher","award":["220728"],"award-info":[{"award-number":["220728"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"Sandia National Laboratories","doi-asserted-by":"publisher","award":["225922"],"award-info":[{"award-number":["225922"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019966","name":"Honeywell","doi-asserted-by":"publisher","award":["SC20\/l 973.01.00"],"award-info":[{"award-number":["SC20\/l 973.01.00"]}],"id":[{"id":"10.13039\/100019966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","award":["National Virtual Biotechnology Laboratory"],"award-info":[{"award-number":["National Virtual Biotechnology Laboratory"]}],"id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to persist, demonstrating the risks posed by emerging infectious diseases to national security, public health, and the economy. Development of new vaccines and antibodies for emerging viral threats requires substantial resources and time, and traditional development platforms for vaccines and antibodies are often too slow to combat continuously evolving immunological escape variants, reducing their efficacy over time. Previously, we designed a next-generation synthetic humanized nanobody (Nb) phage display library and demonstrated that this library could be used to rapidly identify highly specific and potent neutralizing heavy chain-only antibodies (HCAbs) with prophylactic and therapeutic efficacy <jats:italic>in vivo<\/jats:italic> against the original SARS-CoV-2. In this study, we used a combination of high throughput screening and machine learning (ML) models to identify HCAbs with potent efficacy against SARS-CoV-2 viral variants of interest (VOIs) and concern (VOCs). To start, we screened our highly diverse Nb phage display library against several pre-Omicron VOI and VOC receptor binding domains (RBDs) to identify panels of cross-reactive HCAbs. Using HCAb affinity for SARS-CoV-2 VOI and VOCs (pre-Omicron variants) and model features from other published data, we were able to develop a ML model that successfully identified HCAbs with efficacy against Omicron variants, independent of our experimental biopanning workflow. This biopanning informed ML approach reduced the experimental screening burden by 78% to 90% for the Omicron BA.5 and Omicron BA.1 variants, respectively. The combined approach can be applied to other emerging viruses with pandemic potential to rapidly identify effective therapeutic antibodies against emerging variants.<\/jats:p>","DOI":"10.1371\/journal.ppat.1012903","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T18:33:56Z","timestamp":1737657236000},"page":"e1012903","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nanobody screening and machine learning guided identification of cross-variant anti-SARS-CoV-2 neutralizing heavy-chain only antibodies"],"prefix":"10.1371","volume":"21","author":[{"given":"Peter R.","family":"McIlroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thanh Mai","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell A.","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Thatcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Jaryenneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Schwedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris K. A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina R.","family":"Weilhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Negrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Sale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0621-5320","authenticated-orcid":true,"given":"Brooke","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"9","key":"ppat.1012903.ref001","first-page":"e18136","article-title":"Pandemics Throughout the History.","volume":"13","author":"S Sampath","year":"2021","journal-title":"Cureus."},{"issue":"8","key":"ppat.1012903.ref002","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.4103\/jfmpc.jfmpc_2071_20","article-title":"Viral Pandemics in the Past Two Decades: An Overview.","volume":"10","author":"P Bhadoria","year":"2021","journal-title":"J Family Med Prim Care."},{"issue":"7898","key":"ppat.1012903.ref003","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"D Planas","year":"2022","journal-title":"Nature"},{"issue":"7898","key":"ppat.1012903.ref004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"6582","key":"ppat.1012903.ref005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein\u2013ACE2 complex","volume":"375","author":"D Mannar","year":"2022","journal-title":"Science"},{"key":"ppat.1012903.ref006","doi-asserted-by":"crossref","first-page":"125997","DOI":"10.1016\/j.ijbiomac.2023.125997","article-title":"Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants","volume":"249","author":"L Wang","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"ppat.1012903.ref007","article-title":"Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation.","volume":"8","author":"V Sifniotis","year":"2019","journal-title":"Antibodies (Basel)."},{"issue":"1","key":"ppat.1012903.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"RM Lu","year":"2020","journal-title":"J Biomed Sci"},{"issue":"5","key":"ppat.1012903.ref009","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/bib\/bbz095","article-title":"Computational approaches to therapeutic antibody design: established methods and emerging trends","volume":"21","author":"RA Norman","year":"2020","journal-title":"Brief Bioinform"},{"issue":"2","key":"ppat.1012903.ref010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nprot.2016.180","article-title":"Modeling and docking of antibody structures with Rosetta.","volume":"12","author":"BD Weitzner","year":"2017","journal-title":"Nat Protoc."},{"issue":"2","key":"ppat.1012903.ref011","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/prot.22309","article-title":"Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking","volume":"74","author":"A Sivasubramanian","year":"2009","journal-title":"Proteins"},{"issue":"1","key":"ppat.1012903.ref012","doi-asserted-by":"crossref","first-page":"e1000644","DOI":"10.1371\/journal.pcbi.1000644","article-title":"SnugDock: paratope structural optimization during antibody-antigen docking compensates for errors in antibody homology models.","volume":"6","author":"A Sircar","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"ppat.1012903.ref013","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1038\/s41598-021-84637-4","article-title":"Potential neutralizing antibodies discovered for novel corona virus using machine learning.","volume":"11","author":"R Magar","year":"2021","journal-title":"Scientific Reports"},{"issue":"7","key":"ppat.1012903.ref014","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A guide to: generation and design of nanobodies.","volume":"288","author":"S. Muyldermans","year":"2021","journal-title":"Febs j."},{"key":"ppat.1012903.ref015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.csbj.2019.12.005","article-title":"Prediction of human-virus protein-protein interactions through a sequence embedding-based machine learning method.","volume":"18","author":"X Yang","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"issue":"17","key":"ppat.1012903.ref016","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/bioinformatics\/btab147","article-title":"DeepViral: prediction of novel virus-host interactions from protein sequences and infectious disease phenotypes","volume":"37","author":"W Liu-Wei","year":"2021","journal-title":"Bioinformatics"},{"issue":"1","key":"ppat.1012903.ref017","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12859-021-04484-y","article-title":"A multitask transfer learning framework for the prediction of virus-human protein-protein interactions","volume":"22","author":"TN Dong","year":"2021","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"ppat.1012903.ref018","doi-asserted-by":"crossref","first-page":"1958663","DOI":"10.1080\/19420862.2021.1958663","article-title":"Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies.","volume":"13","author":"MA Stefan","year":"2021","journal-title":"MAbs."},{"key":"ppat.1012903.ref019","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.","volume":"8","author":"P Bannas","year":"2017","journal-title":"Front Immunol."},{"issue":"11","key":"ppat.1012903.ref020","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"A Rambaut","year":"2020","journal-title":"Nature Microbiology"},{"issue":"7","key":"ppat.1012903.ref021","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2666-5247(21)00068-9","article-title":"SARS-CoV-2 spike E484K mutation reduces antibody neutralisation","volume":"2","author":"S Jangra","year":"2021","journal-title":"The Lancet Microbe"},{"key":"ppat.1012903.ref022","article-title":"SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies.","author":"DA Collier","year":"2021","journal-title":"medRxiv"},{"key":"ppat.1012903.ref023","first-page":"1059","article-title":"Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections,","volume":"70","year":"2021","journal-title":"Associated with Large Public Gatherings MMWR Morb Mortal Wkly Rep"},{"key":"ppat.1012903.ref024","article-title":"The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.","author":"H Liu","year":"2021","journal-title":"bioRxiv"},{"key":"ppat.1012903.ref025","article-title":"Shedding of Infectious SARS-CoV-2 Despite Vaccination.","author":"KK Riemersma","year":"2021","journal-title":"medRxiv"},{"issue":"4","key":"ppat.1012903.ref026","doi-asserted-by":"crossref","first-page":"612.e1","DOI":"10.1016\/j.cmi.2021.11.010","article-title":"Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study","volume":"28","author":"PY Chia","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"ppat.1012903.ref027","unstructured":"Brooke Nicole Harmon; Peter Riches McIlroy YKL, inventorSARS-CoV-2 variant nanobodies and constructs comprising such nanobodies. US2024."},{"key":"ppat.1012903.ref028","article-title":"Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.","author":"JB Case","year":"2020","journal-title":"bioRxiv"},{"issue":"1","key":"ppat.1012903.ref029","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"AJ Greaney","year":"2021","journal-title":"Nature Communications"},{"key":"ppat.1012903.ref030","article-title":"SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant.","author":"PD Yadav","year":"2021","journal-title":"bioRxiv"},{"issue":"3","key":"ppat.1012903.ref031","doi-asserted-by":"crossref","first-page":"109415","DOI":"10.1016\/j.celrep.2021.109415","article-title":"SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination","volume":"36","author":"M Hoffmann","year":"2021","journal-title":"Cell Reports"},{"issue":"1","key":"ppat.1012903.ref032","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41467-021-21118-2","article-title":"SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity","volume":"12","author":"S Ozono","year":"2021","journal-title":"Nature Communications"},{"issue":"11","key":"ppat.1012903.ref033","doi-asserted-by":"crossref","first-page":"e00921","DOI":"10.1128\/JCM.00921-21","article-title":"Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants","volume":"59","author":"V Tchesnokova","year":"2021","journal-title":"Journal of Clinical Microbiology"},{"issue":"8","key":"ppat.1012903.ref034","doi-asserted-by":"crossref","first-page":"100540","DOI":"10.1016\/j.crmeth.2023.100540","article-title":"Using interpretable machine learning to extend heterogeneous antibody-virus datasets","volume":"3","author":"T Einav","year":"2023","journal-title":"Cell Reports Methods"},{"key":"ppat.1012903.ref035","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76004","article-title":"Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1.","volume":"11","author":"C LaMont","year":"2022","journal-title":"Elife."},{"issue":"7961","key":"ppat.1012903.ref036","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06025-4","article-title":"SARS-CoV-2 Omicron boosting induces de novo B cell response in humans","volume":"617","author":"WB Alsoussi","year":"2023","journal-title":"Nature"},{"issue":"W1","key":"ppat.1012903.ref037","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"A Waterhouse","year":"2018","journal-title":"Nucleic Acids Research"},{"issue":"2","key":"ppat.1012903.ref038","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions","volume":"7","author":"MHM Olsson","year":"2011","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"7","key":"ppat.1012903.ref039","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/ct200133y","article-title":"Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values","volume":"7","author":"CR S\u00f8ndergaard","year":"2011","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"16","key":"ppat.1012903.ref040","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"JC Phillips","year":"2005","journal-title":"J Comput Chem"},{"issue":"1","key":"ppat.1012903.ref041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"J Huang","year":"2017","journal-title":"Nature Methods"},{"issue":"11","key":"ppat.1012903.ref042","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1063\/1.470648","article-title":"Constant pressure molecular dynamics simulation: The Langevin piston method","volume":"103","author":"SE Feller","year":"1995","journal-title":"The Journal of Chemical Physics"},{"issue":"1794","key":"ppat.1012903.ref043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1098\/rspa.1983.0077","article-title":"Simulation of electrostatic systems in periodic boundary conditions. III. Further theory and applications","volume":"388","author":"Perram JW Leeuw SWd","year":"1983","journal-title":"Proceedings of the Royal Society of London A Mathematical and Physical Sciences"},{"issue":"1","key":"ppat.1012903.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v077.i01","article-title":"ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R","volume":"77","author":"MN Wright","year":"2017","journal-title":"Journal of Statistical Software"},{"issue":"11","key":"ppat.1012903.ref045","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/bioinformatics\/btv042","article-title":"protr\/ProtrWeb: R package and web server for generating various numerical representation schemes of protein sequences","volume":"31","author":"N Xiao","year":"2015","journal-title":"Bioinformatics"},{"key":"ppat.1012903.ref046","first-page":"237","article-title":"DRAGON software: An easy approach to molecular descriptor calculations","volume":"56","author":"A Mauri","year":"2006","journal-title":"MATCH Communications in Mathematical and in Computer Chemistry"},{"issue":"1","key":"ppat.1012903.ref047","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"AJ Greaney","year":"2021","journal-title":"Cell Host Microbe"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1012903","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012903","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T18:42:40Z","timestamp":1738694560000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012903"}},"subtitle":[],"editor":[{"given":"Bjoern","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012903","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1012903","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}